Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Trademarks of Remicade & Remsima not confusing
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Aug 28, 2014 12:06:15
The Patent Court ruled that Celltrion didn’t infringe Janssen Korea’s right on its trademark for Remicade, sources said on August 24.

Janssen Korea appealed to the Patent Court immediately after the Intellectual Property Tribunal sided with Celltrion. The court seems that the trademarks of Remicade and Remsima are not confusing when the both are displayed at the same time.

Remsima sales were 3 billion won last year. Remicade sales dropped a little to 28.2 billion won in 2013.

Remsima has been approved for marketing in Europe and already marketed in developing countries. Celltrion’s partner company applied for marketing approval of Remsima in the U.S.

Janssen filed lawsuits to protect its trademark of Remicade in Canada, Republic of South Africa, Philippines, and India.
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com